Search clinical trials for: AN2728 ointment vehicle

Total 2147 results

Pfizer

Completed

Efficacy and Safety of AN2898 and AN2728 Topical Ointments to Treat Mild-to-Moderate Atopic Dermatitis

Dermatitis, Atopic

Australia
Pfizer

Completed

Safety Study of Ointment for the Treatment of Plaque-type Psoriasis (AN2728-PSR-104)

Plaque-type Psoriasis

Australia
Pfizer

Completed

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Psoriasis

Mexico
Pfizer

Completed

Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

Psoriasis

Mexico
Pfizer

Completed

AN2728 Topical Ointment to Treat Mild-to-Moderate Plaque-Type Psoriasis

Psoriasis

United States
Pfizer

Completed

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Ages 2 Years and Older) With Atopic Dermatitis

Dermatitis, Atopic

United States
Pfizer

Completed

Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis

Dermatitis, Atopic

Australia, United States
Pfizer

Completed

Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis

Dermatitis, Atopic

United States
Pfizer

Completed

Safety, Tolerability, and PK of AN2728 in Adolescents With Atopic Dermatitis

Dermatitis, Atopic

United States
Pfizer

Completed

A Phase I Study to Assess Novel Ointment in a Psoriasis Plaque Test

Psoriasis

Germany
Serentis Ltd.

Completed

Safety and Efficacy of SRD441 Ointment in Patients With Atopic Dermatitis

Atopic Dermatitis

Germany, Bulgaria, Finland
GlaxoSmithKline

Completed

A Study of GSK2981278 Ointment in Subjects With Plaque Psoriasis

Psoriasis

Germany
Pfizer

Completed

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis (EMPORIA)

Plaque Psoriasis | Atopic Dermatitis

United States, Australia, Canada, Poland
Pfizer

Completed

Study Evaluating Efficacy and Safety of Crisaborole in Adults With Stasis Dermatitis

Stasis Dermatitis

United States
Dermavant Sciences GmbH

Completed

Study of RVT-501 Topical Ointment in Pediatric Patients With Atopic Dermatitis

Atopic Dermatitis

United States, Canada
UNION therapeutics

Completed

Study to Evaluate Safety & Efficacy of Topical ATx201 OINTMENT in Adolescents and Adults With Mild to Moderate AD

Atopic Dermatitis

Bulgaria, Denmark, Poland
Reistone Biopharma Company Limited

Active, not recruiting

Evaluate the Efficacy and Safety of Topical SHR0302 Ointment in Patients With Mild-to-Moderate Atopic Dermatitis (MARBLE-23)

Atopic Dermatitis

China
OnQuality Pharmaceuticals (USA) LLC

Active, not recruiting

A Study to Investigate OQL011 on VEGFR Inhibitor-Associated Hand-Foot Skin Reaction in Cancer Patients (NOVA-II)

Hand-Foot Skin Reaction (HFSR)

United States, China, India
Healthpoint

Completed

Clinical Evaluation of the Photoallergy Potential of Xenaderm Ointment

Healthy

United States
LEO Pharma

Completed

Proof of Concept, Twice Daily Applications of LEO 124249 Ointment in the Treatment of Chronic Hand Eczema

Hand Eczema

Germany
Dermavant Sciences GmbH

Completed

Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis

Atopic Dermatitis

Canada, United States
Technoderma Medicines Inc.
Therapeutics, Inc.

Recruiting

Study of TDM-180935 in Atopic Dermatitis Patients

Atopic Dermatitis

United States
Pfizer

Completed

A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.

Plaque Psoriasis | Atopic Dermatitis

United States, Canada, United Kingdom, Japan
E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

Completed

A First-in-Human Study of QY101 Ointment in Adult Subjects

Healthy Volunteer

China
Pfizer

Completed

Study to Assess Efficacy and Safety of Two Regimens of Crisaborole Ointment 2% in Japanese Participants Aged ≥2 Years With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

Japan
LEO Pharma

Terminated

Efficacy of Twice Daily Application of LEO 124249 Ointment 30 mg/g for 12 Weeks on Eyebrow Alopecia Areata.

Alopecia Areata

Denmark
Otsuka Pharmaceutical Development & Commercialization...

Completed

A Study to Evaluate the Effectiveness and Safety of Topical OPA-15406 Ointment to Treat Participants With Atopic Dermatitis

Atopic Dermatitis

Poland, United States, Australia
Pfizer

Completed

A Study of Crisaborole Ointment 2% in Adult Japanese Healthy Subjects and Adult Japanese Subjects With Mild To Moderate Atopic Dermatitis

Healthy | Atopic Dermatitis

Japan
Dermavant Sciences GmbH

Completed

A Phase 2 Study of E6005 in Patients With Atopic Dermatitis

Atopic Dermatitis

Japan
Novartis Pharmaceuticals

Completed

A Study Evaluating the Safety and Efficacy of Topical BPR277 for the Treatment of Atopic Dermatitis and Netherton Syndrome (3)

Healthy Volunteers | Atopic Dermatitis | Netherton Syndrome

Netherlands, United States
LEO Pharma

Completed

Trial Twice Daily Application of LEO 124249 Ointment 30 mg/g in Treatment of Mild to Moderate Inverse Psoriasis

Inverse Psoriasis

Germany
LEO Pharma

Completed

LEO 124249 Ointment in the Treatment of Alopecia Areata

Alopecia Areata

United States
Bayer

Completed

Dose Escalation of Different Concentrations of ZK 245186 in Atopic Dermatitis

Atopic Dermatitis

South Africa
Pfizer

Completed

Crisaborole for Chinese and Japanese Subjects (≥2 Years of Age) With Mild to Moderate Atopic Dermatitis

Atopic Dermatitis

China, Japan, Korea, Republic of
Pfizer

Completed

Crisaborole Ointment 2% Skin Biomarker Biopsy Study in Atopic Dermatitis

Dermatitis, Atopic

Canada
Galderma R&D

Completed

Efficacy and Safety Study of CD2027 Ointment 3 Microgram Per Gram (mcg/g) Twice Daily Treatment for Adults With at Least Moderate Atopic Dermatitis

Atopic Dermatitis

United States
Otsuka Beijing Research Institute

Recruiting

To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD

Atopic Dermatitis (AD)

China
Reistone Biopharma Company Limited

Terminated

Assess the Efficacy and Safety of SHR0302 Ointment in Adult Patients With Vitiligo

Vitiligo

China
Pfizer

Completed

A Phase I Study to Assess Novel Cream in a Psoriasis Plaque Test

Psoriasis

Germany
Otsuka Beijing Research Institute

Recruiting

To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD

Atopic Dermatitis (AD)

China
Azura Ophthalmics
Avania

Completed

Evaluation of AZR-MD-001 in Patients With Meibomian Gland Dysfunction (MGD)

Meibomian Gland Dysfunction

Australia, New Zealand
Azura Ophthalmics
ORA, Inc.

Recruiting

A Phase 3 Study to Evaluate AZR-MD-001 in Patients With Abnormal Meibomian Gland Function and Dry Eye Disease (DED)

Dry Eye Disease

United States
University of California, San Diego
Bausch & Lomb Incorporated; Shiley Eye Center

Withdrawn

Efficacy of Loteprednol Ointment Following Eyelid Surgery

Post-operative Healing Following Blepharoplasty and Ptosis Repair

United States
Hovione Scientia Limited

Completed

Study to Evaluate the Safety and Efficacy of Minocycline Ointment in Subjects With Inflamed Meibomian Gland Dysfunction

Meibomian Gland Dysfunction | MGD-Meibomian Gland Dysfunction

United States
Pfizer

Completed

Safety and Efficacy Study of a Novel Ointment to Treat Plaque Type Psoriasis (AN2728PSR203)

Psoriasis

Mexico
Pfizer

Completed

CP-690-550 Ointment For Chronic Plaque Psoriasis

Psoriasis

United States, Canada
QuatRx Pharmaceuticals Company

Completed

Safety and Efficacy Study of Two Dose Regimens of Becocalcidiol in the Treatment of Plaque-Type Psoriasis

Psoriasis

United States
Bausch & Lomb Incorporated

Completed

Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery

Ocular Inflammation

United States
University of Colorado, Denver
Pfizer

Completed

Study of Efficacy, Safety and Tolerability of Crisaborole and PF-07038124 With and Without NBUVB in Vitiligo

Vitiligo

United States
Bayer

Terminated

BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study

Psoriasis

Germany

3

Subscribe